Resultados y vida financieraSalud - Farma - Biotecnología
Inside Information / Other news releases
04/11/2026 17:45
AMFPublicación inmediata
A highly promising commercial roll-out that provides access to one of the world's highestprevalence Irritable Bowel Syndrome (IBS) markets (~27% regional average2 vs. 9.2% globally3)
Mauna Kea Technologies Announces the Launch of CellTolerance® at
Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to
Offer the Program
Cleveland Clinic Abu Dhabi is ranked #1 for gastroenterology in the Middle East1
A highly promising commercial roll-out that provides access to one of the world's highestprevalence Irritable Bowel Syndrome (IBS) markets (~27% regional average2 vs. 9.2% globally3)
CellTolerance empowers physicians to identify food reactions in 70% of IBS patients with negative standard allergy tests4, enabling targeted diets without unnecessary restrictions.
Paris and Boston, November 4th, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the clinical launch of CellTolerance at Cleveland Clinic Abu Dhabi, part of the M42 network and ranked the Middle East's top gastroenterology hospital by Newsweek (see Cleveland Clinic Abu Dhabi's announcement). Following UAE market authorization by the Emirates Drug Establishment in May 2026 and approval by the Department of Health – Abu Dhabi, the hospital's Digestive Disease Institute becomes the first in the Middle East and North Africa (MENA) to offer the CellTolerance program to patients with suspected food-related Irritable Bowel Syndrome (IBS) symptoms.
The Middle East has some of the highest IBS rates in the world. A 2024 systematic review of 52 studies (51,683 participants across seven Arab countries) found that IBS affects approximately 27% of people on average2, compared with a 2020 global meta-analysis estimating worldwide IBS prevalence at 9.2% using Rome III criteria3. In a study published in the American Journal of Gastroenterology, 84% of IBS patients reported symptoms triggered by at least one food5. Yet the standard work-up often fails to find the cause: conventional blood and skin-prick tests detect only classical, IgE-mediated food allergy, so many reactions go undetected. In a prospective study published in Gastroenterology, 70% of IBS patients with negative IgE blood and skinprick tests showed an immediate reaction to at least one common food component under confocal laser endomicroscopy4. Without a way to see these reactions, patients are often left with months or years of trialand-error elimination diets.
The CellTolerance test is designed to replace that guesswork with evidence. The test is performed under sedation during a standard upper gastrointestinal endoscopy that typically takes less than half an hour. During 1 https://www.clevelandclinicabudhabi.ae/en/media-center/news/ccad-ranks-first-in-the-uae-across-five-specialties 2 Almansour O. Prevalence of Irritable Bowel Syndrome (IBS) in the Arab World: A Systematic Review. Cureus. 2024 Jul 26;16(7):e65421. doi:10.7759/cureus.65421